title: Brazilian health-care policy for targeted oncology therapies and companion diagnostic testing.
abstract: A growing understanding of the molecular pathology of tumours combined with a surge of new drugs and associated diagnostic technologies (ie, precision medicine) has translated into substantial improvements in survival for patients with cancer. However, to achieve the promise that precision medicine has to offer will require overcoming hurdles within a national health-care system in which it is to be implemented. Brazil is one such nation, an emerging middle-income country with a very complex health-care system. To address the challenges associated with implementing precision medicine into a country such as Brazil, a group of experts convened (Nov 16-18, 2015, Miami) to discuss challenges related to precision medicine within an oncology setting. Complex regulatory hurdles, a shortage of human and technical resources, and the complexities of a two-tiered health-care delivery system were all identified as the main shortcomings to effectively implementing this new field of medicine. A path forward was proposed that relies on active collaboration between clinicians, private organisations, and government. It seems entirely possible that, despite many intrinsic economic and political problems, Brazil can readily emerge as a model for other countries in Latin America for the potential benefits of precision medicine and companion diagnostics.
authors: D'Or Institute for Research and Education (IDOR), Rio de Janeiro, Brazil. Electronic address: cgmferreira@gmail.com.
authors: Carlos Gil
authors: CG
authors: Ferreira
authors: A C Camargo Cancer Center, São Paulo, Brazil.
authors: Maria Isabel
authors: MI
authors: Achatz
authors: Service of Medical Genetics, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil; Department of Genetics, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
authors: Patricia
authors: P
authors: Ashton-Prolla
authors: A C Camargo Cancer Center, São Paulo, Brazil.
authors: Maria Dirlei
authors: MD
authors: Begnami
authors: Functional Genomics Laboratory, Carlos Chagas Institute, Fiocruz Paraná, Molecular Biology Institute of Paraná, Curitiba, Paraná, Brazil.
authors: Fabricio K
authors: FK
authors: Marchini
authors: Mãe de Deus Cancer Center, Porto Alegre, Brazil.
authors: Stephen Doral
authors: SD
authors: Stefani
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003695:Delivery of Health Care / Q000331:legislation & jurisprudence*; D006291:Health Policy; D006801:Humans; D025202:Molecular Diagnostic Techniques / Q000592:standards*; D058990:Molecular Targeted Therapy / Q000592:standards*; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors*; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D057285:Precision Medicine
chemical_list: D009363:Neoplasm Proteins